N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
N/A N=214 Symptom-Based Markers for COVID-19 Transmission
Covid19
Primary: Body Temperature — 98.1 degrees Fahrenheit
N/A N=93 Rapid, Onsite COVID-19 Detection
COVID-19 · Sars-CoV2
Primary: Number of Samples Tested — 3692 samples
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=246 Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada
SARS-CoV-2 · Covid19 · Corona Virus Infection
Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants
N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
Phase 2 N=101 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
COVID-19
Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants
N/A N=4,733 Test to Stay in School: COVID-19 Testing Following Exposure in School Communities
Covid19
Primary: Number of Students With Positive COVID-19 Test Following Known Within-school Exposure. — 285 Participants
Phase 2 N=42 NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Suspected or Confirmed COVID-19
Primary: Amplicon Sequence Variants (ASVs) That Are Significantly Correlated With Variation in the Microbiome Data Between NBT-NM108 Group and Usual Care Only Group From Day 0 to…
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
N/A N=3 COVID-19 Close Contact Self-Testing Study
Covid19
Primary: Number of Positive Contacts — 0; 0 Participants
N/A N=112 ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff
Children With Medical Complexity (CMC) · COVID-19
Primary: Change in Protocol Uptake: Number of Children and Staff Consented Compared to Number of Approached — 71; 17 Participants
N/A N=614 SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
SARS-CoV-2 Infection · Influenza A · Influenza B
Primary: Qualitative Detection of RNA From SARS-CoV-2, Influenza A, and Influenza B ; Positive Percent Agreement Performance Comparison of Candidate Device (Metrix) vs…
Phase 1 N=53 RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
Covid19
Primary: Total Protein Normal to Abnormal Transition — 4.5; 4.6 percentage of participants — p=1.000
N/A N=14 Rutgers Pilot for PREDICT- Patient POC Test
SARS CoV 2 Infection
Primary: Patient Willingness to Follow Through With the Study Surveys, Triage and Testing — 71.42 percentage of participants
N/A N=877 Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
COVID-19
Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants
N/A N=272 Collection and Testing of Respiratory Samples
QIAGEN ResPlex II Advanced Panel · Influenza A · Respiratory Syncytial Virus Infections
Primary: Detection of Respiratory Viruses — 83 participants
N/A N=300 Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
SARS-CoV 2 · COVID-19
Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18
Phase 4 N=50 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
Phase 3 N=829 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
COVID-19 · Corona Virus Infection · SARS (Severe Acute Respiratory Syndrome)
Primary: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection — 45; 53 Participants
N/A N=392 Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD)
Covid19
Primary: Number Infected With COVID-19 — 29; 141 Participants
Phase 2 N=85 Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
COVID-19
Primary: COVID Ordinal Outcomes Scale at 14 Days — 2.0; 2.0 score on a scale
N/A N=2,778 You and Me COVID Free
COVID-19
Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants